medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 1

<< Back Next >>

Ann Hepatol 2015; 14 (1)

Portal vein thrombosis: What is new?

Manzano-Robleda MC, Barranco-Fragoso B, Uribe M, Méndez-Sánchez N

Language: English
References: 28
Page: 20-27
PDF size: 188.19 Kb.


ABSTRACT

Portal vein thrombosis (PVT) is one of the most common vascular disorders of the liver with significant morbidity and mortality. Large cohort studies have reported a global prevalence of 1%, but in some risk groups it can be up to 26%. Causes of PVT are cirrhosis, hepatobiliary malignancy, abdominal infectious or inflammatory diseases, and myeloproliferative disorders. Most patients with PVT have a general risk factor. The natural history of PVT results in portal hypertension leading to splenomegaly and the formation of portosystemic collateral blood vessels and esophageal, gastric, duodenal, and jejunal varices. Diagnosis of PVT is made by imaging, mainly Doppler ultrasonography. According to its time of development, localization, pathophysiology, and evolution, PVT should be classified in every patient. Some clinical features such as cirrhosis, hepatocellular carcinoma, and hepatic transplantation are areas of special interest and are discussed in this review. The goal of treatment of acute PVT is to reconstruct the blocked veins. Endoscopic variceal ligation is safe and highly effective in patients with variceal bleeding caused by chronic PVT. In conclusion, PVT is the most common cause of vascular disease of the liver and its prevalence has being increasing, especially among patients with an underlying liver disease. All patients should be investigated for thrombophilic conditions, and in those with cirrhosis, anticoagulation prophylaxis should be considered.


REFERENCES

  1. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-64.

  2. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006; 12: 2115-9.

  3. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Sacco M, Martino R, De Nucci C, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34: 535-8.

  4. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31: 366-74.

  5. Rehak M, Rehak J, Müller M, Faude S, Faude F, Siegemund A, Krcova V, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008; 99: 925-9.

  6. Simsek E, Yesilyurt A, Pinarli F, Eyerci N, Ulus AT. Combined genetic mutations have remarkable effect on deep venous thrombosis and/or pulmonary embolism occurrence. Gene 2014; 536: 171-6.

  7. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-41.

  8. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-7.

  9. Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O. Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant 2002; 2: 934-8.

  10. Raja K. Portal Vein Thrombosis in Cirrhosis. J Clin Exp Hepatol 2013; doi.org/10.1016/j.jceh.2013.12.003

  11. Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol 2009; 51: 632-4.

  12. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51: 682-9.

  13. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, et al. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology 2014 In press.

  14. Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M, Gasbarrini A. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol 2009; 104: 1852-4.

  15. Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, Seong J, et al. Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. Cancer Res Treat 2014; 46: 348-57.

  16. Gayowski TJ, Marino IR, Doyle HR, Echeverri L, Mieles L, Todo S, Wagener M, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996; 60: 333-8.

  17. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012; 57: 203-12.

  18. Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. Transplant Rev (Orlando) 2014; 28: 92-101.

  19. Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, Busuttil RW. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg 2009; 208: 896-903.

  20. Chawla Y, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. Aliment Pharmacol Ther 2009; 30: 881-94.

  21. Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 651-61.

  22. Webster GJ, Burroughs AK, Riordan SM. Review article: portal vein thrombosis -new insights into aetiology and management. Aliment Pharmacol Ther 2005; 21: 1-9.

  23. Dilawari JB, Raju GS, Chawla YK. Development of large spleno-adreno-renal shunt after endoscopic sclerotherapy. Gastroenterology 1989; 97: 421-6.

  24. Han G, Qi X, He C, Yin Z, Wang J, Xia J, Yang Z, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011; 54: 78-88.

  25. Yamashita Y, Bekki Y, Imai D, Ikegami T, Yoshizumi T, Ikeda T, Kawanaka H, et al. Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer. Thromb Res 2014; 134: 826-31.

  26. Senzolo M, Caldwell S. Portal vein thrombosis in cirrhosis: ignore, prevent, or treat? Gastroenterology 2013; 144: 19-20.

  27. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60 e1-4.

  28. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010; 123: 111-9.




2020     |     www.medigraphic.com